Serum concentrations of insulin-like growth factor-I (IGF-I) as a marker of liver fibrosis in patients with chronic hepatitis C

Digestive Diseases and Sciences

Volumn 52, Issue 11, 2007, Pages 3245-3250

  Lorenzo Zúñiga, Vicente ^a   Bartolí, Ramon ^a   Masnou, Helena ^a   Montoliu, Silvia ^a   Morillas, Rosa M A ^a   Planas, Ramon ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Chronic hepatitis C; Combined therapy; Liver fibrosis; Serum IGF I levels

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; SOMATOMEDIN C;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOASSAY; INSULIN-LIKE GROWTH FACTOR I; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RNA, VIRAL;

EID: 34848903655     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9437-1     Document Type: Article

References (34)

1. NIH Consensus Statement on Management of Hepatitis C (2002) Hepatology 36:S3-S20
2. Strader DB, Wright T, Thomas DL, Seef LB (2004) AALSD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147-1171
3. Dienstag JL (2002) The role of liver biopsy in chronic hepatitis C. Hepatology 36:S152-S160
4. Castera L, Negre I, Samii K, Buffet C (1999) Pain experienced during percutaneous liver biopsy. Hepatology 30:1529-1530
5. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97:2614-2618
6. Bedossa P, Dargère D, Paradise V (2003) Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38:1449-1457
7. Fontana RJ, Lok AS (2002) Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 36:S57-S64
8. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C (1997) Noninvasive diagnosis of hepatic fibrosis or cirrhosis.Gastroenterology 113:1609-1616
9. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis. C Hepatology 38:518-526
10. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357:1069-1075
11. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E (2002) Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36:986-992
12. Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D (2003) Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 18:253-257
13. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J (1996) Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 42:558-563
14. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R (2004) Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10:429-434
15. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29:1705-1713
16. Sara VR, Hall K (1990) Insulin-like growth factors and their binding proteins. Physiol Rev 70:591-614
17. Schimpff RM, Lebrec D, Donnadieu M (1977) Somatomedin production in normal adults and cirrhotic patients. Acta Endocrinol 86:355-62
18. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3-34
19. Picardi A, Deoliveira AC, Muguerza B, Tosar A, Quiroga J, Castilla-Cortázar I, Santidrián S, Prieto J (1997) Low doses of insulin-like growth factor-I improve nitrogen retention and food efficiency in rats with early cirrhosis. J Hepatol 26:191-202
20. Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N, Vyzantiadis A (2003) Serum concentrations of insulin-like growth factor-I (IGF-I) in patient with liver cirrhosis. Hepatogastroenterology 50:814-6
21. Hattori N, Kurahachi H, Ikekubo K, Ishihara T, Moridera K, Hino M, Saiki Y, Imura H (1992) Serum growth hormone-binding protein, insulin-like growth factor-I, and growth hormone in patients with liver cirrhosis. Metabolism 41:377-381
22. Møller S, Becker U, Juul A, Skakkebbæk NE, Christensen E, EMALD Group (1996) Prognostic value of insulinlike growth factor I and its binding protein in patients with alcohol-induced liver disease. Hepatology 23:1073-8
23. Granada ML, Murillo J, Lucas A, Salinas I, Llopis MA, Castells I, Foz M, Sanmartí A (2000) Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ration and urinary GH measurements in the diagnosis of adult GH deficiency: importance of an appropriate reference population. Eur J Endocrinology 142:243-253
24. Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology 24:289-293
25. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber R (2005) Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41:1376-1382
26. Sedlaczek N, Hasilik A, Neuhaus P, Schuppan D, Herbst H (2003) Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br J Cancer 88:733-739
27. Inaba T, Saito H, Inoue T, Han I, Furukawa S, Matsuda T, Ikeda S, Muto T (1999) Growth hormone/insulin-like growth factor I axis alterations contribute to disturbed protein metabolism in cirrhosis patients after hepatectomy. J Hepatol 31:271-276
28. Castilla-Cortázar I, García M, Muguerza B, Quiroga J, Pérez R, Santidrián S, Prieto J (1997) Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 113:1682-1691
29. Tong MJ, el-Farra NS, Reikes AR, Co RL (1995) Clinical outcomes after transfusion-associated hepatitis C. N Eng J Med 332:1463-6
30. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Hoffman J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982
31. Hadzjyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer HJ, Bernstein D, Rizzeto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM (2004) Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomised study of treatment duration and ribavirin dose. Ann Intern Med 140:346-355
32. Mann MP, McHutchinson JG, Gordon SC, Rusgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2002) Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965
33. National Institutes of Health Consensus Development Conference (2002) National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002. Hepatology 36(suppl 1):S3-S20
34. Poynard T, McHutchison J, David GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J (2000) Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32:1131-1137